Alpha1H BC

Hamlet BioPharma is a clinical-stage biotechnology company headquartered in Lund, Sweden, specializing in the development of targeted cancer therapies. The company's core technology is based on the HAMLET (Human Alpha-lactalbumin Made LEthal to Tumor cells) complex, a protein-lipid molecule that selectively induces apoptosis in cancerous cells. Their lead drug candidate, Alpha1H, is a synthetic peptide derived from HAMLET currently in Phase 2 clinical trials for the treatment of non-muscle invasive bladder cancer. Beyond oncology, the company is expanding its portfolio into infectious diseases following its merger with Selecta Biotech. Hamlet BioPharma is listed on the Spotlight Stock Market and maintains strong academic ties with Lund University. The company's innovative approach aims to provide effective cancer treatments with minimal side effects by exploiting the natural tumor-killing properties of human milk components.